Kelly Boothe

Contacto de Relaciones con Inversores en Carmot Therapeutics, Inc. .

Health Technology

Perfil

Kelly Boothe is currently the Vice President of Investor Relations & Communications at Carmot Therapeutics, Inc. Prior to this role, Dr. Boothe worked as the Senior Director of Communications & Investor Relations at Spyre Therapeutics, Inc.

Cargos activos de Kelly Boothe

Empresas	Cargo	Inicio
Carmot Therapeutics, Inc. Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA.	Contacto de Relaciones con Inversores	-

Todos los cargos activos de Kelly Boothe

Antiguos cargos conocidos de Kelly Boothe.

Empresas	Cargo	Fin
SPYRE THERAPEUTICS, INC.	Contacto de Relaciones con Inversores	-

Ver el detalle de la experiencia de Kelly Boothe.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Kelly Boothe.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
SPYRE THERAPEUTICS, INC.	Health Technology

Empresas privadas	1
Carmot Therapeutics, Inc. Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA.	Health Technology